Valuation: Resverlogix Corp.

Market Cap 18.48M 13.23M 11.81M 10.84M 9.86M 1.25B 18.85M 129M 52.17M 661M 49.64M 48.58M 2.09B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 104M 74.62M 66.62M 61.14M 55.61M 7.06B 106M 730M 294M 3.73B 280M 274M 11.78B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.44%
Yield 2024 *
-
Yield 2025 -
1 week-6.25%
1 month-16.67%
3 months-21.05%
6 months-25.00%
Current year-25.00%
1 week 0.08
Extreme 0.075
0.08
1 month 0.08
Extreme 0.075
0.09
Current year 0.08
Extreme 0.075
0.14
1 year 0.08
Extreme 0.075
0.15
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 25/04/2003
Director of Finance/CFO 78 29/10/2009
Chief Tech/Sci/R&D Officer - 15/08/2022
Director TitleAgeSince
Chairman - 04/04/2016
Director/Board Member 56 15/10/2009
Director/Board Member 66 29/09/2010
Date Insider Type Main position Quantity % Market Cap. Importance
6/7/26 Option

Chief Financial Officer

350,000 0.1018%
6/7/26 Option

Chief Financial Officer

-350,000 0.1018%
6/7/26 Option

Chief Executive Officer

500,000 0.1454%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-6.25%-21.05%0.00% 18.51M
-2.37%-5.03%+39.49%+62.39% 63.77B
-2.87%+0.49%+11.11%+69.18% 56.37B
+0.62%+2.11%+16.96%+102.56% 54.62B
-3.33%-5.54%+19.39%+35.69% 44.06B
-2.45%-2.59%+16.36%+98.45% 42.11B
-1.64%+2.32%+219.80%+789.69% 41B
-5.47%+24.76%+101.20%+87.34% 34.92B
+0.21%+1.05%+14.81%+46.96% 32.82B
-2.90%+17.12%-42.35%+337.07% 24.7B
Average -2.02%+6.15%+37.57%+162.93% 39.44B
Weighted average by Cap. -2.16%+4.83%+44.63%+163.54%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.46M -4.88M -4.48M -4.07M -517M -7.79M -53.47M -21.55M -273M -20.51M -20.07M -862M -7.77M -5.56M -4.96M -4.55M -4.14M -526M -7.92M -54.4M -21.93M -278M -20.86M -20.42M -877M
Net Debt 81.87M 58.59M 52.31M 48M 43.67M 5.55B 83.5M 573M 231M 2.93B 220M 215M 9.25B 85.79M 61.4M 54.82M 50.3M 45.76M 5.81B 87.5M 601M 242M 3.07B 230M 226M 9.69B
Projected Income Statement - Annual - Resverlogix Corp.
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
02/11/26 CA$0.0750 0.00% 4,000
30/10/26 CA$0.0750 -6.25% 42,025
29/10/26 CA$0.0800 +6.67% 20,000
27/10/26 CA$0.0750 -6.25% 3,000